A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PPI / proton pump inhibitor

[Related PubMed/MEDLINE]
Total Number of Papers: 3447
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PPI  (>> Co-occurring Abbreviation)
Long Form:   proton pump inhibitor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 aOR, VREfm
2022 PIM
2022 ---
2022 HP, ITT, RR, VPZ
2022 ---
2022 aOR, CIs
2022 ACS, DAPT, GI
2022 EE, EoE, PPI-nr-EoE, PPI-r-EoE
2022 EndoFLIP, FLIP, POEM
10  2022 CRC
11  2022 A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. CI, GERD, P-CAB, RR, TEAEs
12  2022 A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients. H2RA, PHIS
13  2022 A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy. PGI, UGIE
14  2022 A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia. ACB
15  2022 A rare endoscopic pattern in a patient with gastroesophageal reflux disease. ---
16  2022 A review on lactoferrin as a proton pump inhibitor. LF
17  2022 Acid Suppression and Antibiotics Administered during Infancy Are Associated with Celiac Disease. CD, H2RAs, HR
18  2022 Acute interstitial nephritis observed with three different triggering agents. AIN, AKI, NSAIDs
19  2022 An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding. ---
20  2022 An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis. CIs, HRs, ICIs, OS, PFS
21  2022 Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. BE, NSAID, OR, RE
22  2022 Analysis of effects of laryngopharyngeal reflux disease and proton pump inhibitor treatment on Eustachian tube function in patients with obstructive sleep apnea hypopnea. BMI, ETS-7, LPRD, OSA
23  2022 Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study. CRC, DOAC
24  2022 Antireflux band mucosectomy: a novel minimally invasive approach for the treatment of refractory gastroesophageal reflux disease. ARBM, ARMS, TIF
25  2022 Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn. AET, GERD
26  2022 Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria. GITU, GOPD
27  2022 Associated Mortality Risk of Proton Pump Inhibitor Therapy for the Prevention of Stress Ulceration in Intensive Care Unit Patients: A Systematic Review and Meta-analysis. CI, RCTs
28  2022 Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort. aOR, BPPV, CIs, ORs
29  2022 Association between hospital-acquired pneumonia and proton pump inhibitor prophylaxis in patients treated with glucocorticoids: a retrospective cohort study based on 307,622 admissions in China. HAP
30  2022 Association between Migraines and Prior Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort. ---
31  2022 Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study. DDD, HCC
32  2022 Association of Early Life Prescriptions for Antibiotics and Acid Suppressants with Childhood Psychotropic Prescriptions. aHR, H2RA
33  2022 Association of Proton Pump Inhibitor and Infection and Major Adverse Clinical Events in Patients With ST-Elevation Myocardial Infarction: A Propensity Score Matching Analysis. MACE, PCI, STEMI
34  2022 Autoimmune and immune-mediated inflammatory diseases after exposure to acid-suppressive medication: A systematic review and meta-analysis. H2RA, MC
35  2022 Barriers to Guideline-Based Use of Proton Pump Inhibitors to Prevent Upper Gastrointestinal Bleeding. GI, PCPs
36  2022 Bowel Habit Pattern of Patients with Self-Reported Constipation at Out Patient Department in North East Part of Bangladesh. ---
37  2022 Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study. ---
38  2022 Clinical efficacy of endoscopic antireflux mucosectomy vs. Stretta radiofrequency in the treatment of gastroesophageal reflux disease: a retrospective, single-center cohort study. ARMS, GEFV, GERD, GERD-HRQL, GerdQ, SRF
39  2022 Clinical Endoscopic and Histologic Findings of a Long-Term Follow-Up (10.7 Years) After Roux-en-Y Laparoscopic Gastric Bypass: a Prospective Study. BE, BMI, GERD, LYGB
40  2022 Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough. ---
41  2022 Clinical outcomes of asymptomatic low-grade esophagitis: results from a multicenter Chinese cohort. GERD
42  2022 Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study. AEs, CI, HR, mCRC, ORR, OS, TTF
43  2022 Clinical profile and characteristics of eosinophilic esophagitis patients presenting with refractory gastroesophageal reflux disease in Makassar, Indonesia. GERD
44  2022 Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements. AET, GERD, RAM
45  2022 Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. GERD, SAP
46  2022 Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. ---
47  2022 Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study. CIs, HRs
48  2022 Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. GERD, MNBI, PSPWI
49  2022 Clinical, histopathological features and efficacy of elimination diet and proton-pump inhibitor therapy in achieving histological remission in Asian children with eosinophilic gastritis. EG, FED, HPF
50  2022 Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors. CDI, ICIs, IMDC
51  2022 Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. BQT, H. pylori, L-TT, M-TT
52  2022 Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study. CI, H2RA, HR
53  2022 Cost Analysis of Implementing an Exercise Program for Fall and Fracture Prevention in Older Adults on Proton Pump Inhibitor Therapy. ---
54  2022 Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. CV, GI, ICER, LDA, QALYs
55  2022 Diagnostic thresholds and optimal collection protocol of salivary pepsin for gastroesophageal reflux disease. AM, GERD, PM
56  2022 Direct-to-consumer strategies to promote deprescribing in primary care: a pilot study. ---
57  2022 Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. ROBINS-I, RRs
58  2022 Dose-Dependent Proton Pump Inhibitor Exposure and Risk of Type 2 Diabetes: A Nationwide Nested Case-Control Study. cDDD, CI, OR, OR, T2DM, UGID
59  2022 Drug treatment strategies for eosinophilic esophagitis in adults. EoE, STCs
60  2022 Drug-Related Problems in Bariatric Surgery: a Retrospective Study. DRPs, NCC MERP, PFT
61  2022 Effect of aluminum phosphate gel on prevention of early rebleeding after ligation of esophageal variceal hemorrhage. APG, EVB, EVL, PPI group
62  2022 Effect of Proton Pump Inhibitor on the Outcome of Laryngeal Microsurgery in Patients With Vocal Fold Mucosal Disease With Reflux Symptoms. GRBAS, LMS, NHR, RSI, VF, VHI-10
63  2022 Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients. CI, HR, OS, PFS
64  2022 Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). HDDT
65  2022 Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. CI, H. pylori, RR, VPZ
66  2022 Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. DDD, GPs
67  2022 Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. CI, HR, iPFS, IPTW, OR, OS, UC
68  2022 Effectiveness of Proton-Pump Inhibitors in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials. CIs, COPD, MD, RCTs, RRs
69  2022 Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. CYP2C19, EM, H. pylori, PM, PPIs, RCTs
70  2022 Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study. PA, pwCF
71  2022 Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab. CI, HR, ICIs, OS, PFS
72  2022 Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. ICI, mRCC
73  2022 Efficacy and safety of laparoscopic Roux-en-Y gastric bypass in symptomatic patients following fundoplication failure: a meta-analysis. BMI, GERD, LF, LRYGB, RLF
74  2022 Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis. CI, GERD, GERD-HRQL, LES, RR
75  2022 Eighteen-year-old man with syncope with Helicobacter pylori as the culprit: a case report. GI, H. pylori, PUD
76  2022 Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. BQT, CI, H. pylori, ITT, PP
77  2022 Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? H. pylori
78  2022 Esophageal Microbiome in Healthy Children and Esophageal Eosinophilia. EE, EoE, RE
79  2022 Esophagitis Dissecans Superficialis: A Frequently Missed and Rarely Reported Diagnosis. EDS
80  2022 Establishing the Association Between Osteoporosis and Peptic Ulcer Disease: A Systematic Review. PMC, PUD, RCTs
81  2022 Exposure to Proton Pump Inhibitors and the Risk of Incident Asthma in Patients with Coronary Artery Diseases: A Population-Based Cohort Study. CAD, CIs, H2RA, HRs
82  2022 Factors associated with gastro-duodenal ulcer in compensated type 2 diabetic patients: a Romanian single-center study. ---
83  2022 Factors related to delayed adverse events of endoscopic submucosal dissection in the duodenum. D-ESD
84  2022 First-line therapies for H. pylori infection in Italy: a pooled-data analysis. ---
85  2022 Fungal digestive enzymes promote macronutrient hydrolysis in the INFOGEST static in vitro simulation of digestion. GI, ONS
86  2022 Gastric neuroendocrine tumor after prolonged use of proton pump inhibitor. NET
87  2022 Gastrointestinal Bleeding Risk Factors in Patients with Type 2 Diabetes Mellitus. ASA, BMI, CHF, CKD, CVD, GIB, NOAC, NSAID
88  2022 Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease. EPZ, GERD, P-CAB
89  2022 High-dose proton pump inhibitors are associated with hospitalisation in bronchiectasis exacerbation. H2RA
90  2022 Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients. H2RA
91  2022 Impact of Acid Suppression Therapy on Renal and Survival Outcomes in Patients with Chronic Kidney Disease: A Taiwanese Nationwide Cohort Study. CKD, ESRD, H2RA
92  2022 Impact of Helicobacter pylori Infection and Outcome of Anti-Helicobacter pylori Therapy in Patients with Reflux Laryngopharyngitis. HP, RFS, RLP, RSI
93  2022 Impact of proton pump inhibitor management committee's multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments. ---
94  2022 Impact of proton pump inhibitors on sustained virologic response in veterans treated with sofosbuvir/velpatasvir for chronic hepatitis C virus: A retrospective cohort study. HCV, SOF/VEL, SVR
95  2022 Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. ICI, NSCLC, OS, PFS
96  2022 Impact of Second-Generation Transoral Incisionless Fundoplication on atypical GERD symptoms: A Systematic Review and Meta-analysis. RSI, TIF
97  2022 Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study. H2RA, ICU, SUP
98  2022 Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells. DOC, ESOM, ROB, siRNA
99  2022 Interaction between xylanase and a proton pump inhibitor on broiler chicken performance and gut function. AX, AXOS, FCR, VFA
100  2022 Intermittent Versus Continuous Infusion Dosing of Intravenous Proton Pump Inhibitors for Upper Gastrointestinal Bleeding. ICU, UGIB